These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

595 related items for PubMed ID: 26361879

  • 1. Two-year radiographic and clinical outcomes from the Canadian Methotrexate and Etanercept Outcome study in patients with rheumatoid arthritis.
    Keystone EC, Pope JE, Thorne JC, Poulin-Costello M, Phan-Chronis K, Vieira A, Haraoui B, CAMEO Investigators.
    Rheumatology (Oxford); 2016 Feb; 55(2):327-34. PubMed ID: 26361879
    [Abstract] [Full Text] [Related]

  • 2. The Effect of Reduced or Withdrawn Etanercept-methotrexate Therapy on Patient-reported Outcomes in Patients with Early Rheumatoid Arthritis.
    Wiland P, Dudler J, Veale D, Tahir H, Pedersen R, Bukowski J, Vlahos B, Williams T, Gaylord S, Kotak S.
    J Rheumatol; 2016 Jul; 43(7):1268-77. PubMed ID: 27252426
    [Abstract] [Full Text] [Related]

  • 3. A randomized comparative effectiveness study of oral triple therapy versus etanercept plus methotrexate in early aggressive rheumatoid arthritis: the treatment of Early Aggressive Rheumatoid Arthritis Trial.
    Moreland LW, O'Dell JR, Paulus HE, Curtis JR, Bathon JM, St Clair EW, Bridges SL, Zhang J, McVie T, Howard G, van der Heijde D, Cofield SS, TEAR Investigators.
    Arthritis Rheum; 2012 Sep; 64(9):2824-35. PubMed ID: 22508468
    [Abstract] [Full Text] [Related]

  • 4. Short-term efficacy of etanercept plus methotrexate vs combinations of disease-modifying anti-rheumatic drugs with methotrexate in established rheumatoid arthritis.
    Fleischmann R, Koenig AS, Szumski A, Nab HW, Marshall L, Bananis E.
    Rheumatology (Oxford); 2014 Nov; 53(11):1984-93. PubMed ID: 24907147
    [Abstract] [Full Text] [Related]

  • 5. Comparison of etanercept and methotrexate, alone and combined, in the treatment of rheumatoid arthritis: two-year clinical and radiographic results from the TEMPO study, a double-blind, randomized trial.
    van der Heijde D, Klareskog L, Rodriguez-Valverde V, Codreanu C, Bolosiu H, Melo-Gomes J, Tornero-Molina J, Wajdula J, Pedersen R, Fatenejad S, TEMPO Study Investigators.
    Arthritis Rheum; 2006 Apr; 54(4):1063-74. PubMed ID: 16572441
    [Abstract] [Full Text] [Related]

  • 6. When to adjust therapy in patients with rheumatoid arthritis after initiation of etanercept plus methotrexate or methotrexate alone: findings from a randomized study (COMET).
    Dougados MR, van der Heijde DM, Brault Y, Koenig AS, Logeart IS.
    J Rheumatol; 2014 Oct; 41(10):1922-34. PubMed ID: 25128520
    [Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8. Etanercept versus methotrexate in patients with early rheumatoid arthritis: two-year radiographic and clinical outcomes.
    Genovese MC, Bathon JM, Martin RW, Fleischmann RM, Tesser JR, Schiff MH, Keystone EC, Wasko MC, Moreland LW, Weaver AL, Markenson J, Cannon GW, Spencer-Green G, Finck BK.
    Arthritis Rheum; 2002 Jun; 46(6):1443-50. PubMed ID: 12115173
    [Abstract] [Full Text] [Related]

  • 9. Maintenance of remission with combination etanercept-DMARD therapy versus DMARDs alone in active rheumatoid arthritis: results of an international treat-to-target study conducted in regions with limited biologic access.
    Pavelka K, Akkoç N, Al-Maini M, Zerbini CAF, Karateev DE, Nasonov EL, Rahman MU, Pedersen R, Dinh A, Shen Q, Vasilescu R, Kotak S, Mahgoub E, Vlahos B.
    Rheumatol Int; 2017 Sep; 37(9):1469-1479. PubMed ID: 28597306
    [Abstract] [Full Text] [Related]

  • 10. Predictors of remission with etanercept-methotrexate induction therapy and loss of remission with etanercept maintenance, reduction, or withdrawal in moderately active rheumatoid arthritis: results of the PRESERVE trial.
    Smolen JS, Szumski A, Koenig AS, Jones TV, Marshall L.
    Arthritis Res Ther; 2018 Jan 16; 20(1):8. PubMed ID: 29338762
    [Abstract] [Full Text] [Related]

  • 11. Disconnect between inflammation and joint destruction after treatment with etanercept plus methotrexate: results from the trial of etanercept and methotrexate with radiographic and patient outcomes.
    Landewé R, van der Heijde D, Klareskog L, van Vollenhoven R, Fatenejad S.
    Arthritis Rheum; 2006 Oct 16; 54(10):3119-25. PubMed ID: 17009230
    [Abstract] [Full Text] [Related]

  • 12. Targeting ultrasound remission in early rheumatoid arthritis: the results of the TaSER study, a randomised clinical trial.
    Dale J, Stirling A, Zhang R, Purves D, Foley J, Sambrook M, Conaghan PG, van der Heijde D, McConnachie A, McInnes IB, Porter D.
    Ann Rheum Dis; 2016 Jun 16; 75(6):1043-50. PubMed ID: 27026689
    [Abstract] [Full Text] [Related]

  • 13. Abatacept plus methotrexate provides incremental clinical benefits versus methotrexate alone in methotrexate-naive patients with early rheumatoid arthritis who achieve radiographic nonprogression.
    Wells AF, Westhovens R, Reed DM, Fanti L, Becker JC, Covucci A, Keystone EC.
    J Rheumatol; 2011 Nov 16; 38(11):2362-8. PubMed ID: 21885491
    [Abstract] [Full Text] [Related]

  • 14. Impact of flare on radiographic progression after etanercept continuation, tapering or withdrawal in patients with rheumatoid arthritis.
    Smolen JS, Pedersen R, Jones H, Mahgoub E, Marshall L.
    Rheumatology (Oxford); 2020 Jan 01; 59(1):153-164. PubMed ID: 31257453
    [Abstract] [Full Text] [Related]

  • 15. Attainment and characteristics of clinical remission according to the new ACR-EULAR criteria in abatacept-treated patients with early rheumatoid arthritis: new analyses from the Abatacept study to Gauge Remission and joint damage progression in methotrexate (MTX)-naive patients with Early Erosive rheumatoid arthritis (AGREE).
    Smolen JS, Wollenhaupt J, Gomez-Reino JJ, Grassi W, Gaillez C, Poncet C, Le Bars M, Westhovens R.
    Arthritis Res Ther; 2015 Jun 11; 17(1):157. PubMed ID: 26063454
    [Abstract] [Full Text] [Related]

  • 16. Radiographic and clinical outcomes following etanercept monotherapy in Japanese methotrexate-naïve patients with active rheumatoid arthritis.
    Takeuchi T, Miyasaka N, Pedersen R, Sugiyama N, Hirose T.
    Mod Rheumatol; 2020 Mar 11; 30(2):259-268. PubMed ID: 30836801
    [Abstract] [Full Text] [Related]

  • 17. Efficacy of tofacitinib in patients with rheumatoid arthritis stratified by background methotrexate dose group.
    Fleischmann R, Mease PJ, Schwartzman S, Hwang LJ, Soma K, Connell CA, Takiya L, Bananis E.
    Clin Rheumatol; 2017 Jan 11; 36(1):15-24. PubMed ID: 27734232
    [Abstract] [Full Text] [Related]

  • 18. Prediction of DAS28-ESR remission at 6 months by baseline variables in patients with rheumatoid arthritis treated with etanercept in Japanese population.
    Iwamoto N, Kawakami A, Fujikawa K, Aramaki T, Kawashiri SY, Tamai M, Arima K, Ichinose K, Kamachi M, Yamasaki S, Nakamura H, Nakashima M, Mizokami A, Goto A, Fukuda T, Matsuoka N, Ueki Y, Tsukada T, Migita K, Shoumura F, Kawabe Y, Shibatomi K, Mine M, Ida H, Origuchi T, Aoyagi K, Eguchi K.
    Mod Rheumatol; 2009 Jan 11; 19(5):488-92. PubMed ID: 19578932
    [Abstract] [Full Text] [Related]

  • 19. Clinical, functional, and radiographic implications of time to treatment response in patients with early rheumatoid arthritis: a posthoc analysis of the PREMIER study.
    Keystone EC, Haraoui B, Guérette B, Mozaffarian N, Liu S, Kavanaugh A.
    J Rheumatol; 2014 Feb 11; 41(2):235-43. PubMed ID: 24293583
    [Abstract] [Full Text] [Related]

  • 20. Clinical, functional, and radiographic benefits of longterm adalimumab plus methotrexate: final 10-year data in longstanding rheumatoid arthritis.
    Keystone EC, van der Heijde D, Kavanaugh A, Kupper H, Liu S, Guérette B, Mozaffarian N.
    J Rheumatol; 2013 Sep 11; 40(9):1487-97. PubMed ID: 23818718
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 30.